To observe the clinical efficacy and safety of evolocumab injection combined with rosuvastatin tablets in the treatment of patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI).

The AMI patients were randomly divided into control group and treatment group. The control group was given oral rosuvastatin at an initial dose of 10 mg daily, if the level of low-density lipoprotein cholesterol (LDL-C) >1.4 mmol·L^-1, the dose was increased to 20 mg daily. On the basis of control group, the treatment group received evolocumab 140 mg, subcutaneous injection of the abdomen, once every 2 weeks. Two groups were treated for 6 months. The clinical efficacy, myocardial injury markers, lipid metabolism parameters, overall incidence of cardiovascular events and safety were compared between two groups.

Treatment group were enrolled 55 cases, 2 cases dropped out, and 53 cases were finally included in the statistical analysis. Control group were enrolled 53 cases, 1 case dropped out, and 52 cases were finally included in the statistical analysis. After treatment, the total effective rates of treatment and control groups were 92.45% (49 cases/53 cases) and 78.85% (41 cases / 52 cases), with statistically significant difference (P<0.05). After treatment, the levels of high-sensitivity cardiac troponin were (2.02±0.61) and (2.78±0.73) ng·L^-1, the levels of creatine kinase-MB were (38.90±6.47) and (50.05±6.15) U·L^-1, the levels of total cholesterol were (2.27±0.15) and (3.15±0.19) mmol·L^-1, the levels of triglycerides were (1.61±0.12) and (1.77±0.17) mmol·L^-1, the levels of LDL-C were (1.25±0.15) and (2.08±0.13) mmol·L^-1, the overall incidences of cardiovascular events were 5.77% and 16.98%, respectively. The differences of above indexes were statistically significant (all P<0.05). The adverse drug reactions of treatment group were skin rash, elevated creatine kinase and liver injury, while those in the control group were nausea and vomiting, skin rash and liver injury. The total incidences of adverse drug reactions in treatment and control groups were 9.43% and 5.77%, without statistically significant difference (P>0.05).

Evolocumab injection combined with rosuvastatin tablets has a definitive clinical efficacy in the treatment of patients with AMI after PCI, which can significantly improve cardiac function, reduce the risk of myocardial injury and cardiovascular events, with good safety.